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ABSTRACT
A 79-year-old man underwent trans-catheter
aortic valve replacement for symptomatic
severe aortic stenosis with a 26-mm Edwards
SAPIEN XT valve. Immediately after valve
deployment there was moderate amount of
paravalvular leak. Post-dilation was performed
with an additional 2 cc of volume, and the
paravalvular leak was reduced to trace. Nine
months later, trans-thoracic echocardiography
revealed moderate to severe paravalvular leak
and possible aortic migration of the valve. The
patient was brought back for the treatment of
the paravalvular leak which was suspected to be
due to valve migration. However, fluoroscopy
and trans-esophageal echocardiography showed
good valve position. Measurement of late valve
recoil in the Coplanar view using
cine-angiographic analysis software showed
that the lower third of the valve had the
greatest late recoil (-1.74 mm, 6.55%), which
presumably accounted for the progression of
the paravalvular leak. Valve-in-valve
trans-catheter aortic valve replacement was
performed with a 26-mm SAPIEN 3 valve and
the paravalvular leak was reduced to trace. This
case displays late recoil as a likely mechanism
for development of paravalvular leak after
SAPIEN XT valve implantation. Our case
illustrates that late recoil needs to be
systematically evaluated in future studies,
especially when trans-catheter aortic valve
replacement is being expanded to lower risk
and younger patients for whom the longevity
and long-term performance of these valves is of
critical importance.
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
0237F0602E31F4A7.
A. Karimi  K. E. Park  C. Y. Choi  K. Mogali 
A. A. Bavry
Division of Cardiovascular Medicine, Department of
Medicine, University of Florida, Gainesville, FL, USA
N. Pourafshar
Division of Nephrology, Hypertension and Renal
Transplantation, Department of Medicine,
University of Florida, Gainesville, FL, USA
K. E. Park  C. Y. Choi  W. W. Stinson 
E. W. Manning  A. A. Bavry (&)
North Florida/South Georgia Veterans Health
System, Gainesville, FL, USA
e-mail: anthony.bavry@va.gov
W. W. Stinson  E. W. Manning
Division of Thoracic and Cardiovascular Surgery,




Keywords: Aortic regurgitation; Trans-catheter
aortic valve replacement; Valve-in-valve
INTRODUCTION
Paravalvular leak (PVL) has been described as
the Achilles’ heel of trans-catheter aortic valve
replacement (TAVR). Moderate or greater degree
of PVL has been clearly associated with
increased mortality, and some studies have
even shown an association between mild PVL
and all-cause mortality [1–3]. What happens to
PVL during the follow-up period is a matter of
debate. Early experience with TAVR raised the
concern that progression of PVL could lead to
volume overload of the left ventricle resulting
in heart failure symptoms or hemolysis and
consequent blood transfusion necessitating
re-intervention. In the first PARTNER trial,
which used the first-generation SAPIEN valve
(Edwards Lifesciences Inc., Irvine, CA), PVL had
worsened by C1 grade at 2 years of follow-up in
22.4% of patients [1, 2]. Like other vascular
scaffolds, such as coronary stents, the
supporting stent scaffold of the TAVR valves is
subject to acute and late recoil, and late recoil
has been postulated as a potential mechanism
of progression of PVL; however, this mechanism
has not yet been described in the literature.
CASE REPORT
A 79-year-old man with a history of
hypertension, diabetes, prior coronary bypass,
atrial fibrillation, carotid artery stenosis, colon
cancer, and frailty who had been turned down
for surgical AVR at his referring hospital
underwent TAVR for symptomatic severe
aortic stenosis with a 26-mm SAPIEN XT valve
(Edwards Lifesciences Inc.). Computed
tomography prior to the procedure showed
minimal amount of aortic annular
calcification—the calcium volume was
1670 mm3 and mainly deposited in the valve
leaflets (Fig. 1a). The aortic valve annular area
measured 459 mm2, which corresponded to
15.7% oversizing. Immediately after the
SAPIEN XT valve deployment there was
moderate amount of PVL (Enhanced Content
Video 1). Acute valve recoil was measured at
three levels in the Coplanar view by subtracting
valve diameters immediately after balloon
deflation from the valve diameters at
maximum balloon inflation. Measurements
were performed with the image processing
software from the Philips Xcelera package
(Philips Medical Systems, Veenpluis, The
Netherlands). Using this software, calibration
was performed on a straight segment of a
contrast-filled pigtail catheter several
centimeters from its tip using the known
diameter of the catheter based on its French
size. After calibration, the valve scaffold was
measured from outer edge to outer edge in the
coplanar view at three levels: high, mid, and
low level. The numbers were reported as
absolute values and as the percentage of the
valve diameter at maximum balloon inflation.
The valve had -0.45 mm (1.68%) recoil at the
higher level, -1.01 mm (3.77%) recoil at the
mid-level, and -0.66 mm (2.49%) recoil at the
lower level (Fig. 1b). Post-dilation was
performed with 2 cc of extra volume, and the
PVL was reduced to trace (Enchanced Content
Video 2). Acute valve recoil was re-measured
and the valve had -1.1 mm (4%) recoil at the
higher level, -1.02 mm (3.75%) recoil at the
mid-level, and -0.14 mm (0.52%) recoil at the
lower level (Fig. 1c). Nine months later, a
trans-thoracic echocardiography performed for
atypical chest pain showed moderate to severe
PVL and possible aortic migration of the valve
(Enhanced Content Video 3). The patient was
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brought back for the treatment of PVL which
was suspected to be due to valve migration.
Trans-esophageal echocardiography confirmed
severe PVL and showed three separate
regurgitation jets in the mid-esophageal
short-axis view (lower left inset of Video 4 in
Enhanced Content). However, fluoroscopy and
trans-esophageal echocardiography showed
good valve position and no evidence of valve
migration (Fig. 2, Video 4). To discover the
mechanism for PVL progression we decided to
measure the amount of late recoil. To this end,
we obtained three angiographic cine images in
the coplanar view, in the same projection that
the initial TAVR had been performed. Valve
diameters were measured at three levels from
these films and averaged (Fig. 1d). Late recoil
was calculated by subtracting the average
numbers at each level from valve diameters
after balloon deflation at the post-dilation
phase of the initial TAVR (middle table in
Fig. 1c). Late recoil was measured to be
-0.91 mm (3.45%) at the higher level,
-1.44 mm (5.5%) at the mid-level, and
-1.74 mm (6.55%) at the lower level of the
valve (Fig. 1d). Therefore, the lower level of the
valve showed the greatest amount of late recoil,
which in our opinion was the mechanism for
progression of the PVL. The summation of acute
and late recoil at 12 months was
Fig. 1 Native valve morphology and acute and late recoil
of the SAPIEN XT valve. a Computed tomography
showing heavily calciﬁed native aortic valve leaﬂets with no
calciﬁcation of the aortic valve annulus, b acute recoil of
the 26-mm SAPIEN XT valve after initial deployment,
c acute recoil after post-dilation with 2 cc of extra volume,
d late recoil 12 months after valve implantation, which
displays the greatest recoil along the lower third of the
valve
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(4.00 ? 3.45 = 7.45%) at the higher level,
(3.75 ? 5.50 = 9.25%) at the mid-level, and
(0.52 ? 6.55 = 7.07%) at the lower level of the
valve. To treat the PVL, valve-in-valve TAVR was
performed with a 26-mm SAPIEN 3 valve
(Edwards Lifesciences Inc.) and the PVL was
reduced to trace (Enhanced Content Video 5).
Informed consent was obtained from the
patient for receiving treatment.
DISCUSSION
The incidence of PVL has been reduced
significantly as a result of more accurate valve
sizing based on computed tomography
measurements, availability of the 29-mm valve
in addition to the 23-mm valve, and the 26-mm
valve as a third size option, improved operators’
skills, and innovative valve designs. The upshot
of studies that have reported degree of PVL at
different follow-up points is that the incidence
of moderate or greater PVL decreases during the
follow-up period in most patients [4]. The
reduction in incidence of moderate or greater
PVL in the follow-up could be due to increased
mortality of patients who had or developed
moderate to severe PVL or it could be related to
remodeling of the aortic valve annulus.
Echocardiographic analysis of patients
participating in the PARTNER trial, which used
the first-generation SAPIEN valve, showed that
at 2 years of follow-up PVL remained the same
in 46.2% of patients, improved in 31.5%, and
worsened by C1 grade in 22.4% [1, 2]. Studies
have not specifically looked at the progression
of PVL with the newer generation SAPIEN XT or
SAPEIN 3 valves over time, but PVL remains an
important complication of TAVR. In Cohort A
of the PARTNER II trial, which used the
second-generation SAPIEN XT valve in
intermediate-risk patients, moderate to severe
PVL was reported in 3.7% of patients at 30 days
of follow-up and was associated with a hazard
ratio of 2.85 for all-cause mortality in the
follow-up period compared to patients with no
PVL or trace PVL [5]. In Cohort B of the
PARTNER II trial, which compared SAPIEN XT
to the first-generation SAPIEN valve in
inoperable patients, the reported incidence of
moderate to severe PVL with the SAPIEN XT
valve was markedly higher than that reported in
other studies—24.2% at 30 days of follow-up
and 27.5% at 1 year [6]. The higher rate of PVL
in that study was speculated to be due to the
ambiguity and difficulty in quantifying PVL and
the tendency of the echocardiography core
laboratory to overestimate its amount. It has
however been postulated that acute and late
recoil are at least partially responsible for the
development and progression of PVL.
To date, only two studies have systemically
assessed acute recoil of the Edwards
balloon-expandable valves. Both studies only
included the first-generation SAPIEN valve and
the second-generation SAPIEN XT valve, and
both reported higher degree of acute recoil with
the SAPIEN XT valve [7, 8].
Fig. 2 Stable position of the SAPIEN XT valve with no
evidence of valve migration. Root angiography and
ﬂuoroscopy show stable valve position: a valve position
at initial deployment, b valve position 12 months later
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The stent scaffold of the SAPIEN XT valve is
made of cobalt–chromium (CoCr) alloy as
opposed to stainless steel which is used in
the first-generation SAPIEN valve, but the stent
struts of the SAPIEN XT valve are thinner than
those of the older generation SAPIEN valve. For
the same strut thickness, CoCr alloy is stiffer
and more resistant to recoil than stainless steel.
This quality is exploited to reduce the
thickness of the stent struts and the crimped
valve profile to allow delivery of the valve
through a smaller sheath. Thinner stent struts,
however, reduce the stiffness of the valve
scaffold, making it more prone to recoil.
Additionally, the SAPIEN XT stent scaffold
possesses three rungs of struts instead of the
four rungs present in the older generation
SAPIEN valve, which also makes it more
susceptible to recoil. To our knowledge, late
recoil has not been previously investigated or
measurably reported nor has acute recoil of the
SAPIEN 3 valve been studied. The SAPIEN 3
stent scaffold is made of CoCr alloy and
consists of five rungs of struts with a wider
strut angle. These characteristics provide
higher radial strength to keep circularity
compared to the SAPIEN XT valve (internal
data provided by Edward Lifesciences Inc.)
[9, 10] and likely make the SAPIEN 3 valve
less prone to recoil compared to the SAPIEN
XT valve; however, the degree of acute or late
recoil of the SAPIEN 3 valve has not yet been
studied in vivo. Nevertheless, we postulate
recoil would have less effect on PVL of the
SAPIEN 3 valve, given the presence of the outer
skirt, and therefore we chose to treat our
patient with the SAPIEN 3 valve. In a large
observational study of slightly over 1000
patients, the SAPIEN 3 valve was associated
with 3.4% incidence of moderate to severe PVL
at the 30-day follow-up [11] and only 2% at 1
year [12].
It is also worthwhile mentioning that
although we initially suspected aortic
migration of the valve as the mechanism for
progression of the PVL, late aortic migration of
TAVR valves is an extremely rare phenomenon,
and late migration of the TAVR valve is most
commonly retrograde towards the left ventricle
as opposed to towards the aorta. Interestingly, a
computational fluid dynamics model showed
that the antegrade force exerted on the TAVR
valve during ejection is tenfold weaker than the
retrograde force applied to it in diastole, which
would explain why late migration tends to
occur towards the left ventricular outflow tract
[13].
CONCLUSION
Acute and late recoil are mechanisms for
development and progression of PVL. Studies
have shown an average 3.75–5.18% of acute
recoil associated with the SAPIEN XT valve
depending on the valve size or the study
[7, 8]. This case report shows late recoil as the
likely mechanism for progression of PVL during
follow-up after a 26-mm SAPIEN XT
implantation and in summation shows
7.07–9.25% of acute plus late recoil at
different valve levels at 1 year of follow-up.
The effect of valve recoil on PVL has not been
previously studied. Future studies need to
systematically evaluate and report acute and
late recoil and how they affect PVL.
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